SELLAS Life Sciences (SLS) Change in Account Payables (2010 - 2026)
SELLAS Life Sciences (SLS) reported Change in Account Payables of $685000.0 for Q1 2026, up 147.29% year-over-year from $277000.0 in Q1 2025, and up 3.79% quarter-over-quarter from $660000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Change in Account Payables (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 17 years of Change in Account Payables data on file, last reported at $685000.0 in Q1 2026.
- Change in Account Payables for Q1 2026 came in at $685000.0, up 147.29% year-over-year; the trailing twelve-month figure through Mar 2026 was -$127000.0 (up 96.54% YoY), and the FY2025 annual result was -$535000.0, up 74.99% from the prior year.
- Change in Account Payables advanced to $685000.0 in Q1 2026 per SLS's latest filing, from $660000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $1.8 million in Q1 2024 and troughed at -$1.8 million in Q3 2024.
- A 5-year average of $89705.9 and a median of $528000.0 in 2022 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2022 and 2024: Change in Account Payables sank 550.56% in 2022, then jumped 735.92% in 2024.
- A 5-year view of Change in Account Payables shows it stood at $1.2 million in 2022, then grew by 7.15% to $1.3 million in 2023, then slumped by 184.83% to -$1.1 million in 2024, then surged by 159.03% to $660000.0 in 2025, then advanced by 3.79% to $685000.0 in 2026.
- Business Quant data shows SLS's Change in Account Payables at $685000.0 in Q1 2026, $660000.0 in Q4 2025, and -$1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | 685,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 685,000.00 |
| Mar 31, 2026 | 685,000.00 |
| Dec 31, 2025 | 660,000.00 |
| Dec 31, 2025 | 660,000.00 |
| Sep 30, 2025 | -1.03 Mn |
| Sep 30, 2025 | -1.03 Mn |
| Jun 30, 2025 | -441,000.00 |
| Jun 30, 2025 | -441,000.00 |
| Mar 31, 2025 | 277,000.00 |
| Mar 31, 2025 | 277,000.00 |
| Dec 31, 2024 | -1.12 Mn |
| Dec 31, 2024 | -1.12 Mn |
| Sep 30, 2024 | -1.77 Mn |
| Sep 30, 2024 | -1.77 Mn |
| Jun 30, 2024 | -1.06 Mn |
| Jun 30, 2024 | -1.06 Mn |
| Mar 31, 2024 | 1.81 Mn |
| Mar 31, 2024 | 1.81 Mn |
| Dec 31, 2023 | 1.32 Mn |
| Dec 31, 2023 | 1.32 Mn |